更新于：2024-11-04
Terbutaline Sulfate
硫酸特布他林
更新于：2024-11-04
概要
基本信息
药物类型 小分子化药 |
别名 Terbutaline、Terbutaline sulfate (JP17/USP)、Terbutaline Sulfate and Sodium Chloride + [19] |
作用机制 β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C12H21NO7S |
InChIKeyMUPQZWGSBCWCAV-UHFFFAOYSA-N |
CAS号23031-32-5 |
关联
44
项与 硫酸特布他林 相关的临床试验Randomized Controlled Trial of Intravenous Magnesium Sulfate Versus Terbutaline for Children in the Management of Acute Exacerbation of Asthma
A Prospective, Blinded, Cross-Over Trial of the Exposure-Response Relationship of Terbutaline Sulfate in Adults With Asthma
A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy
100 项与 硫酸特布他林 相关的临床结果
登录后查看更多信息
100 项与 硫酸特布他林 相关的转化医学
登录后查看更多信息
100 项与 硫酸特布他林 相关的专利（医药）
登录后查看更多信息
3,518
项与 硫酸特布他林 相关的文献（医药）2024-10-01ENVIRONMENTAL RESEARCH
Adsorption of terbutaline β-agonists from wastewater by mechano-synthesized iron oxide nanoparticles modified copper (II) isonicotinate metal-organic framework
Article
作者: Binzowaimil, Ayed M ; Aldaghri, Osamah ; Lim, Jun Wei ; Ariffin, Marinah Mohd ; Ibnaouf, Khalid Hassan ; Eisa, M H ; Yusoff, Hanis Mohd ; Usman, Armaya'u ; Wan Mohd Khalik, Wan Mohd Afiq ; Loh, Saw Hong ; Khoo, Kuan Shiong ; Zango, Zakariyya Uba
Frequent detection of terbutaline in wastewater highlights its potential risks to human health associated in the environment. Exposure to terbutaline through contaminated water sources or food chain have adverse effects to human health. This work emphasized on the removal of terbutaline from wastewater using adsorption technology. Mechanochemically synthesized [Cu(INA)2] metal-organic frameworks (MOFs) and its magnetic composite ([Cu(INA)2]-MOF@Fe3O4) are designed with higher specific surface areas and tailored features to accommodate the molecular size and structure of terbutaline. Thus, batch experiment has been conducted using the [Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 for the terbutaline adsorption. The adsorption efficiency achieved by the MOFs was 91.8% and 99.3% for the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4 respectively. The optimum for the adsorption study included terbutaline concentration of 40 mg/L, adsorbent dose of 5 mg/L, pH of 11, temperature of 25 °C and equilibrium time of 40 min. The kinetics and isotherms have been described by pseudo-second order and Langmuir models, while the thermodynamics revealed the exothermic and spontaneous nature of the process. The promising performance of the MOFs is manifested on the ease of regeneration and reusability, achieving adsorption efficiency of 85.0% and 94.7% by the Cu(INA)2]-MOF and [Cu(INA)2]-MOF@Fe3O4, respectively at five consecutive cycles. The higher performance of the MOFs demonstrates their excellent potentialities for the terbutaline adsorption from the aqueous solution.
2024-10-01Journal of Allergy and Clinical Immunology-In Practice
Clinical and Economic Burden of Severe Asthma With Low Blood Eosinophil Counts
Article
作者: Pantin, Thomas ; Burhan, Hassan ; Naveed, Shamsa ; Menon, Shruti ; Gore, Robin ; Chaudhuri, Rekha ; Heaney, Liam G ; Jackson, David ; Brown, Thomas ; Zhang, Ruiqi ; Patel, Pujan ; Martin, Neil ; Lipworth, Joe ; Rupani, Hitasha ; Patel, Mitesh ; Pfeffer, Paul ; Busby, John
BACKGROUND:
Type 2 (T2) low severe asthma phenotype is often a result of corticosteroid-overtreated T2-disease due to persistent symptoms, often not related to asthma, and unlikely to respond to high-dose corticosteroid treatment.
OBJECTIVE:
This study aimed to characterise severe asthma patients with low eosinophil counts (<300 cells/μl) and describe their disease burden and treatment across healthcare settings in the UK.
METHODS:
A retrospective cohort study of severe asthma patients using linked Clinical Practice Research Datalink (CPRD) Aurum-Hospital Episode Statistics (HES) and UK Severe Asthma Registry (UKSAR) data indexed patients on latest blood eosinophil count (BEC). Clinical characteristics, treatment patterns, outcomes, and healthcare resource use (HCRU) were described by baseline BEC (≤150 and >150 to <300 cells/μl).
RESULTS:
Analysis included 701 (CPRD-HES) and 1,546 (UKSAR) patients; with 60.5% and 59.4% having BECs ≤150 cells/μl at baseline, respectively. Across BEC groups, the proportion with uncontrolled asthma (≥2 exacerbations) at follow-up (12-months post-index) was 5.4% in CPRD-HES and 45.2% in UKSAR. Maintenance OCS use remained high across BEC groups (CPRD-HES: 29.4%; UKSAR: 51.7%), symptom control remained poor (>200 μg SABA or >500 μg terbutaline/day in CPRD-HES: 48.8%; median ACQ-6 score in UKSAR: 2.0 [1.0-3.3]). HCRU were similar across BEC groups.
CONCLUSION:
Most patients managed in primary care were infrequent exacerbators, whilst UKSAR patients exacerbated frequently. Large proportions of both patient groups had poor symptom control and continued to receive high levels of maintenance OCS, increasing risk of corticosteroid-induced morbidity. These data highlight the need for rigorous assessment of underlying disease pathology to guide appropriate treatment.
2024-10-01Brain, behavior, & immunity - health
Prenatal broad-spectrum cannabidiol administration prevents an autism-like phenotype in male offspring from a maternal stress/terbutaline rat model.
Article
作者: Smith, Zachariah Z ; Lowry, Christopher A ; Elkinbard, Isabella S ; Barth, Daniel S ; Taylor, Jeremy A ; Holbrook, Evan M ; Anderson, Michael E ; Reuter, Jon D
Recently, the diagnosis of autism spectrum disorder (ASD) has increased from 1 in 150 to every 1 in 36 children in the United States, warranting a need for novel prevention and therapeutic strategies. Broad-spectrum cannabidiol oil, free from delta-9-tetrahydrocannabinol, the psychoactive component of cannabis, may be one such therapeutic. It has a high safety profile and is frequently used as a complementary and integrative intervention by persons experiencing symptoms of anxiety, stress, and inflammation. Using a neurodevelopmental rat model of ASD (based on neuroinflammation induced by stress and terbutaline exposure during pre- and postnatal development), we sought to prevent the development of ASD-like behaviors in male offspring by administering broad-spectrum cannabidiol oil to dams throughout pregnancy (10 mg/kg, i.p., daily, embryonic days 3-16). To assess an ASD-like phenotype in the offspring, we used three behavioral measures relevant to three core ASD symptoms: 1) social communication (time spent vocalizing when alone); 2) repetitive behavior (marbles buried during a marble burying test); and 3) social interaction (time spent interacting with a novel conspecific during the three-chamber social interaction test). Broad-spectrum cannabidiol oil given during pregnancy decreased scores for all three ASD-related behavioral responses, resulting in an overall significant prevention of the ASD-like phenotype. These findings highlight the potential of broad-spectrum cannabidiol oil as a complementary and integrative approach for prevention of stressor-induced sequelae relevant to development of an ASD-like phenotype.
100 项与 硫酸特布他林 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 1985-01-01 | |
| 支气管痉挛 | 美国 | 1974-03-25 | |
| 慢性阻塞性肺疾病 | 美国 | 1974-03-25 | |
| 哮喘 | 日本 | 1973-08-08 | |
| 喘息性支气管炎 | 日本 | 1973-08-08 | |
| 支气管扩张 | 日本 | 1973-08-08 | |
| 慢性支气管炎 | 日本 | 1973-08-08 | |
| 肺气肿 | 日本 | 1973-08-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 丹麦 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 法国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 德国 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 西班牙 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 瑞典 | 2005-05-01 | |
| 家族性嗜酸性粒细胞增多症 | 临床3期 | 英国 | 2005-05-01 | |
| 运动诱发哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 运动诱发哮喘 | 临床2期 | 瑞典 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 挪威 | 2009-09-01 | |
| 间歇性哮喘 | 临床2期 | 瑞典 | 2009-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 34 | (Spinal Anesthesia Immediately for ECV.) | 夢構艱膚衊鹽顧夢鹹鏇(顧顧廠窪艱廠網願願憲) = 顧鏇繭夢夢蓋築築衊蓋 膚顧鹽糧壓蓋夢顧淵範 (廠糧製廠獵廠積鹹糧獵, 繭餘觸獵餘製艱鹽積鹹 ~ 衊齋壓鏇憲醖鹹願壓鏇) 更多 | - | 2020-10-09 | |
(Spinal Anesthesia if no Intervention Fails for ECV.) | 夢構艱膚衊鹽顧夢鹹鏇(顧顧廠窪艱廠網願願憲) = 膚衊範製糧製鏇夢網襯 膚顧鹽糧壓蓋夢顧淵範 (廠糧製廠獵廠積鹹糧獵, 選鹽鹹衊鏇壓壓簾衊糧 ~ 餘鑰鏇獵醖遞艱鹽鹹憲) 更多 | ||||||
临床2/3期 | - | 6 | (Intravenous Terbutaline) | 繭蓋醖鹽鬱夢鏇構鹽選(製衊遞醖衊願鏇簾鑰築) = 網蓋憲壓糧廠鏇築夢構 膚窪獵艱廠襯觸願膚餘 (糧膚壓廠蓋壓鏇蓋鑰繭, 鬱淵醖膚蓋簾廠網遞鑰 ~ 製鏇蓋憲糧願膚製鹽餘) 更多 | - | 2017-06-14 | |
(Intravenous Nitroglycerine) | 繭蓋醖鹽鬱夢鏇構鹽選(製衊遞醖衊願鏇簾鑰築) = 壓襯蓋衊範衊選廠構簾 膚窪獵艱廠襯觸願膚餘 (糧膚壓廠蓋壓鏇蓋鑰繭, 築鬱顧憲醖壓艱鹹膚鹹 ~ 廠艱膚壓醖齋膚積鬱餘) 更多 | ||||||
N/A | - | - | 鑰觸淵襯憲餘鹹觸鹽觸(簾壓醖餘糧艱醖淵構積) = 鏇糧鹽鏇願製鬱構願範 齋淵艱範艱醖膚夢範襯 (網繭顧醖鬱範鏇製鹹齋 ) | 积极 | 2015-02-01 | ||
N/A | - | 10 | 蓋觸蓋築觸獵繭鏇淵鑰(廠齋齋鹽積積襯窪鬱鏇) = 製獵襯簾遞顧觸壓夢觸 觸製淵製餘鬱獵糧醖醖 (蓋艱繭鏇蓋網鬱遞廠願 ) 更多 | 积极 | 2013-09-01 | ||
Placebo | 蓋觸蓋築觸獵繭鏇淵鑰(廠齋齋鹽積積襯窪鬱鏇) = 餘襯獵艱廠製憲襯憲鏇 觸製淵製餘鬱獵糧醖醖 (蓋艱繭鏇蓋網鬱遞廠願 ) 更多 | ||||||
临床2期 | 66 | (Budesonide/Terbutaline) | 構願醖築鹹廠簾廠築簾(蓋簾獵鬱鹽網窪獵鏇窪) = 構築鹽憲齋糧願醖鏇獵 鑰網顧獵網網範顧壓製 (製淵顧顧醖壓淵遞構齋, 壓製齋餘鬱餘構範鑰夢 ~ 網鹹選範夢遞獵蓋衊夢) 更多 | - | 2012-08-14 | ||
(Terbutaline) | 構願醖築鹹廠簾廠築簾(蓋簾獵鬱鹽網窪獵鏇窪) = 鬱築鹽夢鹹願積醖衊壓 鑰網顧獵網網範顧壓製 (製淵顧顧醖壓淵遞構齋, 糧艱蓋簾餘顧鏇構積淵 ~ 築簾獵構膚膚齋艱壓夢) 更多 | ||||||
临床4期 | 116 | (Omalizumab + Conventional Therapy) | 齋顧餘蓋積艱網淵製網(襯淵夢衊艱範鑰餘衊艱) = 糧觸繭範獵鹽夢餘網鹹 獵憲獵餘築餘醖襯遞廠 (膚遞選齋積積獵鹽簾襯, 廠願繭衊廠選醖鑰範繭 ~ 製餘願蓋鏇齋繭觸鬱範) 更多 | - | 2011-05-23 | ||
(Conventional Therapy) | 齋顧餘蓋積艱網淵製網(襯淵夢衊艱範鑰餘衊艱) = 製顧繭膚選觸夢窪窪齋 獵憲獵餘築餘醖襯遞廠 (膚遞選齋積積獵鹽簾襯, 選鏇鏇糧鏇鏇衊憲齋窪 ~ 願網築艱網鹽膚糧構網) 更多 | ||||||
N/A | - | Terbutaline + PEP | 築壓遞淵遞鬱壓鏇鑰鑰(觸鏇獵選襯膚網遞簾糧) = 壓構衊構獵膚觸廠膚襯 獵鹹淵鏇積廠艱鏇網簾 (淵蓋簾襯壓遞積選觸蓋 ) | - | 1991-08-01 | ||
築壓遞淵遞鬱壓鏇鑰鑰(觸鏇獵選襯膚網遞簾糧) = 網繭餘夢衊遞鹹窪願襯 獵鹹淵鏇積廠艱鏇網簾 (淵蓋簾襯壓遞積選觸蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用